BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND RPN1, OST1, 6184, ENSG00000163902, P04843
18 results:

  • 1. Venetoclax plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukemia ineligible for intensive chemotherapy: an expanded access study in Japan.
    Asada N; Ando J; Takada S; Yoshida C; Usuki K; Shinagawa A; Ishizawa K; Miyamoto T; Iida H; Dobashi N; Okubo S; Honda H; Soshin T; Nishimura Y; Tsutsui A; Mukai H; Yamamoto K
    Jpn J Clin Oncol; 2023 Jun; 53(7):595-603. PubMed ID: 37017320
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
    Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
    Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Treatment patterns and comparative analysis of non-intensive regimens in elderly acute myeloid leukemia patients-a real-world experience from India.
    Kanakasetty GB; R C; K C L; Dasappa L; Jacob LA; M C SB; K N L; Haleshappa RA; L K R; Saldanha SC; Deepak K; Rajesh P; Asati V
    Ann Hematol; 2019 Apr; 98(4):881-888. PubMed ID: 30697642
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Multicentre surveillance study on feasibility, safety and efficacy of antifungal combination therapy for proven or probable invasive fungal diseases in haematological patients: the SEIFEM real-life combo study.
    Candoni A; Caira M; Cesaro S; Busca A; Giacchino M; Fanci R; Delia M; Nosari A; Bonini A; Cattaneo C; Melillo L; Caramatti C; Milone G; Scime' R; Picardi M; Fanin R; Pagano L;
    Mycoses; 2014 Jun; 57(6):342-50. PubMed ID: 24373120
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies.
    Duhoux FP; Ameye G; Montano-Almendras CP; Bahloula K; Mozziconacci MJ; Laibe S; Wlodarska I; Michaux L; Talmant P; Richebourg S; Lippert E; Speleman F; Herens C; Struski S; Raynaud S; Auger N; Nadal N; Rack K; Mugneret F; Tigaud I; Lafage M; Taviaux S; Roche-Lestienne C; Latinne D; Libouton JM; Demoulin JB; Poirel HA; ;
    Br J Haematol; 2012 Jan; 156(1):76-88. PubMed ID: 22050763
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Conventional cytogenetics and breakpoint distribution by fluorescent in situ hybridization in patients with malignant hemopathies associated with inv(3)(q21;q26) and t(3;3)(q21;q26).
    De Braekeleer E; Douet-Guilbert N; Basinko A; Bovo C; Guéganic N; Le Bris MJ; Morel F; De Braekeleer M
    Anticancer Res; 2011 Oct; 31(10):3441-8. PubMed ID: 21965759
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. [A case of t(3;3)(q21;q26.2) associated with severe multilineage dysplasia and multi-drug resistance in blastic crisis of chronic myelogenous leukemia].
    Lee SA; Lim J; Kim M; Kim Y; Han K
    Korean J Lab Med; 2010 Dec; 30(6):595-9. PubMed ID: 21157145
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Development of a dual-color, double fusion FISH assay to detect rpn1/EVI1 gene fusion associated with inv(3), t(3;3), and ins(3;3) in patients with myelodysplasia and acute myeloid leukemia.
    Shearer BM; Sukov WR; Flynn HC; Knudson RA; Ketterling RP
    Am J Hematol; 2010 Aug; 85(8):569-74. PubMed ID: 20556821
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Trends in incidence of childhood cancer in Australia, 1983-2006.
    Baade PD; Youlden DR; Valery PC; Hassall T; Ward L; Green AC; Aitken JF
    Br J Cancer; 2010 Feb; 102(3):620-6. PubMed ID: 20051948
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [Classification of myeloid leukemias].
    Kuriyama K
    Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Multipoint interphase FISH analysis of chromosome 3 abnormalities in 28 childhood AML patients.
    Haltrich I; Kost-Alimova M; Kovács G; Klein G; Fekete G; Imreh S
    Eur J Haematol; 2006 Feb; 76(2):124-33. PubMed ID: 16405433
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells.
    Lahortiga I; Agirre X; Belloni E; Vázquez I; Larrayoz MJ; Gasparini P; Lo Coco F; Pelicci PG; Calasanz MJ; Odero MD
    Oncogene; 2004 Jan; 23(1):311-6. PubMed ID: 14712237
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Association of 3q21q26 syndrome with different rpn1/EVI1 fusion transcripts.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Borsaru G; Visani G; Piccaluga PP; Malagola M; Testoni N; Rondoni M; Nucifora G; Tura S; Baccarani M
    Haematologica; 2003 Nov; 88(11):1221-8. PubMed ID: 14607750
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Low expression of MDS1-EVI1-like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemia.
    Barjesteh van Waalwijk van Doorn-Khosrovani S; Erpelinck C; Löwenberg B; Delwel R
    Exp Hematol; 2003 Nov; 31(11):1066-72. PubMed ID: 14585371
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Breakpoints at 1p36.3 in three MDS/AML(M4) patients with t(1;3)(p36;q21) occur in the first intron and in the 5' region of MEL1.
    Xinh PT; Tri NK; Nagao H; Nakazato H; Taketazu F; Fujisawa S; Yagasaki F; Chen YZ; Hayashi Y; Toyoda A; Hattori M; Sakaki Y; Tokunaga K; Sato Y
    Genes Chromosomes Cancer; 2003 Mar; 36(3):313-6. PubMed ID: 12557231
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21).
    Shimizu S; Suzukawa K; Kodera T; Nagasawa T; Abe T; Taniwaki M; Yagasaki F; Tanaka H; Fujisawa S; Johansson B; Ahlgren T; Yokota J; Morishita K
    Genes Chromosomes Cancer; 2000 Mar; 27(3):229-38. PubMed ID: 10679911
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Toxic reactions of oxidized LDL on cells of acute myeloid leukemia.
    Vahrenwald F; Galka K; Jürgens G; Bruchelt G; Girgert R; Schweizer P
    Leuk Res; 1997; 21(11-12):1071-6. PubMed ID: 9444941
    [TBL] [Abstract] [Full Text] [Related]  


    of 1.